<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00267592</url>
  </required_header>
  <id_info>
    <org_study_id>IXR-207-21-189 / NABTT 0304</org_study_id>
    <nct_id>NCT00267592</nct_id>
    <nct_alias>NCT00082992</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of Talampanel in Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Trial of Talampanel in Conjunction With Radiation Therapy With Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate overall survival for adult patients with newly&#xD;
      diagnosed glioblastoma multiforme treated with talampanel during radiation therapy with&#xD;
      concurrent and adjuvant temozolomide. This study will also determine the toxicity and&#xD;
      toxicity rate of talampanel for this therapeutic regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Talampanel-related toxicity</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>enzyme-inducing antiseizure drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.</description>
    <arm_group_label>enzyme-inducing antiseizure drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy (RT) 5 days a week +</intervention_name>
    <arm_group_label>enzyme-inducing antiseizure drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide(TMZ) 75mg</intervention_name>
    <description>temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks</description>
    <arm_group_label>enzyme-inducing antiseizure drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant TMZ 200mg</intervention_name>
    <description>adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.</description>
    <arm_group_label>enzyme-inducing antiseizure drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be 18 years of age&#xD;
&#xD;
          -  Patients must have histologically confirmed supratentorial Grade IV astrocytoma&#xD;
             (glioblastoma multiforme)&#xD;
&#xD;
          -  Patients must not have prior radiation therapy, chemotherapy (including Gliadel&#xD;
             wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.&#xD;
             Glucocorticoid therapy is allowed.&#xD;
&#xD;
          -  Patients must have recovered from the immediate post-operative period and be&#xD;
             maintained on a stable corticosteroid regimen (on increase for 5 days) prior to the&#xD;
             start of treatment.&#xD;
&#xD;
          -  Patients must have a Karnofsky performance of at least 60% or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with serious concurrent infection or medical illness.&#xD;
&#xD;
          -  Patients receiving concurrent chemotherapeutics or investigational agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 19, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2005</study_first_posted>
  <disposition_first_submitted>August 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 23, 2011</disposition_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

